Retrospective Database Analysis to Explore Patterns and Economic Burden of Switchback to Brand After Generic or Authorized Generic Utilization

• DOI: 10.2147/ceor.s319796
• Publication Date: 2022-04-27T04:20:05Z
• Authors: Justine Alderfer; Jyoti Aggarwal; Kim Gilchrist; Jose Maria Jimene...; Joseph Cook; Sang Hee Park; Jennifer M Stephens
• Keywords: Brand names; Market share

Despite demonstration of bioequivalence generics to brands and the potential for reduced costs, some patients switch back from a generic brand. A prior retrospective analysis suggested that this switchback rate may be lower among had initially switched authorized (AG), often both produced marketed by brand company, compared those another generic.Explore switching patterns brands, AGs, generics, rates, impact switchbacks on healthcare costs.An Pharmetrics Plus™ database (2007-2019), United States (US) payer administrative database, was conducted examine use Upjohn medications available as AGs across multiple therapeutic areas. Patients initiating treatment with medication in 6 months market entry were identified rates well evaluated. Costs descriptively between who remained any generic.Across 14 medications, more than half generic. Generally, AG, which ranged 0.5 39.6%, non-AG (16.7-79.9%). The comparison non-AGs showed similar results (AG:1.3-7.5%; non-AG:1.4-12.9%); however, most substantial differences observed where higher. AG or an average 1-3 (32-88 days). tendency towards increased medical costs period immediately preceding all except sildenafil indications (erectile dysfunction pulmonary arterial hypertension). For remaining $63 $1544 higher population. Pharmacy similarly tended switchback, exception hypertension sirolimus.Patients receiving are likely upon availability. Some medication, usually within months; associated costs. Additional research is needed understand switching, its disruption patients, role AGs.